China's SFDA To Set Up System For New Drug Application, Approval And Appraisal
This article was originally published in PharmAsia News
China's State FDA has released 44 drug databases to publicize all China-marketed drugs on its official website (http://www.sda.gov.cn/). The public can check 980,000 drug items, as well as medical devices and health products, for authenticity and effectiveness/functions, before making a purchase. The agency is also building the database for cosmetic products. Information on drug appraisal is now more transparent: companies that submit new drug applications can enquire online about the status during the drugs' prelaunch safety and efficacy appraisal process at the drug evaluation center website (http://www.cde.org.cn/). The major steps of new drug application, appraisal and approval have been fully divided to prevent unrestricted power that may lead to corruption and safety lapses. (Click here for more - Chinese Language)
You may also be interested in...
A flurry of financial appointments has been seen across the off-patent industry, involving major players Dr Reddy’s, Biocon, Mayne Pharma and Xbrane Biopharma.
Aurobindo has agreed to sell its US-based Natrol dietary supplements business at a significant premium to the $132.5m it paid in late 2014, as the Indian firm continues to drive into complex formulations in the US, including injectables and biosimilars.
GlaxoSmithKline’s third quarter results included a 9% decline in sales in its vaccine business, but this was offset by tight cost controls and restructuring benefits; the company expects to continue investing in its pipeline and new product launches.